Potential for improvement of docetaxel-based chemotherapy: a pharmacological review (Q33218801)

24 July 2017

1 reference

25 January 2021

Potential for improvement of docetaxel-based chemotherapy: a pharmacological review (English)

1 reference

non-small-cell lung carcinoma

24 July 2017

1 reference

7 November 2019

1 reference

25 January 2021

1 reference

7 November 2019

1 reference

25 January 2021

1 reference

1 reference

phytogenic antineoplastic agents

1 reference

25 January 2021

1 reference

25 January 2021

F K Engels

1

1 reference

24 July 2017

A Sparreboom

series ordinal

2

1 reference

24 July 2017

R A A Mathot

series ordinal

3

1 reference

24 July 2017

J Verweij

series ordinal

4

1 reference

24 July 2017

language of work or name

English

0 references

publication date

1 July 2005

1 reference

British Journal of Cancer

24 July 2017

25 July 2005

5 references

13 March 2019

3 April 2019

17 June 2019

7 November 2019

25 January 2021

6 references

24 July 2017

13 March 2019

3 April 2019

17 June 2019

7 November 2019

25 January 2021

93

1 reference

24 July 2017

2

1 reference

24 July 2017

173-177

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6602698

24 July 2017

0 references

cites work

Docetaxel administration schedule: from fever to tears? A review of randomised studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361544

Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361544

Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361544

MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361544

Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361544

Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361544

Use of the erythromycin breath test for in vivo assessments of cytochrome P4503A activity and dosage individualization

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361544

Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361544

Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361544

Phase I and pharmacokinetic study of a new taxoid, RPR 109881A, given as a 1-hour intravenous infusion in patients with advanced solid tumors

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361544

Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361544

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361544

A population pharmacokinetic model for docetaxel (Taxotere): model building and validation

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361544

Relationship of systemic exposure to unbound docetaxel and neutropenia.

28 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602698

Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602698

Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602698

Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602698

Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602698

Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602698

Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602698

Dexamethasone as a probe for docetaxel clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602698

DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602698

Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602698

Docetaxel and ketoconazole in advanced hormone-refractory prostate carcinoma: a phase I and pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602698

Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602698

Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361544

Optimizing the erythromycin breath test for use in cancer patients.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361544

The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16012521

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/SJ.BJC.6602698

1 reference

Dimensions Publication ID

24 July 2017

0 references

1 reference

24 July 2017

1 reference